Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Patient care guidelines: problems and solutions.

Robert G Narins1, William M Bennett

  • 1American Society of Nephrology, Washington, DC, USA.

Clinical Journal of the American Society of Nephrology : CJASN
|August 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and Validation of a Multivariable Prediction Model for Kidney Failure in Early Autosomal Dominant Polycystic Kidney Disease.

Journal of the American Society of Nephrology : JASN·2026
Same author

Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation.

Kidney international·2023
Same author

Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease.

Clinical journal of the American Society of Nephrology : CJASN·2022
Same author

Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease.

Kidney international reports·2021
Same author

Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease.

Clinical journal of the American Society of Nephrology : CJASN·2019
Same author

Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.

Kidney international·2019
Same journal

A Patient's Perspective on Arteriovenous Fistula Care and Far-Infrared Radiation Arteriovenous Fistula Therapy.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

A Beacon of Hope: Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

Sequential Biomarker Testing in Kidney Transplant Surveillance: How Far Does One Step at a Time Take Us?

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

The Predicting Risk of Cardiovascular Disease Event Equation Meets CKD.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

Muscle Cramp Rate, Severity and Burden in Maintenance Hemodialysis Patients: A Yearlong Multicenter Quality Improvement Initiative.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

From Risk Determinants to Clinical Action: Understanding and Implementing the Cardiovascular Kidney Metabolic Syndrome Framework.

Clinical journal of the American Society of Nephrology : CJASN·2026
See all related articles

This CJASN issue discusses industry influence on Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines for anemia treatment in chronic kidney disease and end-stage renal disease (ESRD). Further expert and reader opinions will be featured in upcoming publications.

Area of Science:

  • Nephrology
  • Medical Guidelines
  • Healthcare Policy

Background:

  • The Kidney Disease Outcomes Quality Initiative (KDOQI) provides critical patient care guidelines.
  • Anemia is a common complication in chronic kidney disease (CKD) and end-stage renal disease (ESRD).
  • Interactions between healthcare guideline development and industry funding are a subject of ongoing debate.

Purpose of the Study:

  • To present discussions on the interplay between pharmaceutical industry involvement and KDOQI guidelines.
  • To explore potential influences on treatment recommendations for anemia in CKD and ESRD patients.
  • To foster a dialogue on transparency and potential conflicts of interest in guideline creation.

Main Methods:

  • Presentation of two distinct viewpoints on industry interactions with KDOQI guidelines.

Related Experiment Videos

  • Focus on the specific context of anemia management in CKD and ESRD.
  • Planned inclusion of invited commentaries and reader opinions in future issues.

    • Main Results:

    • Highlights controversies surrounding industry influence on KDOQI anemia guidelines.
    • Identifies the need for continued discussion and expert input.
    • Sets the stage for broader engagement on guideline integrity.

    Conclusions:

    • The relationship between industry and clinical practice guidelines requires careful scrutiny.
    • Open discussion is essential for maintaining the objectivity of patient care standards.
    • Future publications will expand on these critical issues in nephrology.